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Abstract
Background: Trachoma has been endemic in The Gambia for decades. National trachoma control activities have been in
place since the mid-1980’s, but with no mass antibiotic treatment campaign. We aimed to assess the prevalence of active
trachoma and of actual ocular Chlamydia trachomatis infection as measured by polymerase chain reaction (PCR) in the two
Gambian regions that had had the highest prevalence of trachoma in the last national survey in 1996 prior to planned
national mass antibiotic treatment distribution in 2006.
Methodology/Principal Findings: Two stage random sampling survey in 61 randomly selected Enumeration Areas (EAs) in
North Bank Region (NBR) and Lower River Region (LRR). Fifty randomly selected children aged under 10 years were
examined per EA for clinical signs of trachoma. In LRR, swabs were taken to test for ocular C. trachomatis infection.
Unadjusted prevalences of active trachoma were calculated, as would be done in a trachoma control programme. The
prevalence of trachomatous inflammation, follicular (TF) in the 2777 children aged 1–9 years was 12.3% (95% CI 8.8%–
17.0%) in LRR and 10.0% (95% CI 7.7%–13.0%) in NBR, with significant variation within divisions (p,0.01), and a design
effect of 3.474. Infection with C. trachomatis was found in only 0.3% (3/940) of children in LRR.
Conclusions/Significance: This study shows a large discrepancy between the prevalence of trachoma clinical signs and
ocular C. trachomatis infection in two Gambian regions. Assessment of trachoma based on clinical signs alone may lead to
unnecessary treatment, since the prevalence of active trachoma remains high but C. trachomatis infection has all but
disappeared. Assuming that repeated infection is required for progression to blinding sequelae, blinding trachoma is on
course for elimination by 2020 in The Gambia.
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Introduction
Trachoma is the leading infectious cause of blindness world-
wide.[1] It is caused by repeated re-infection with the ocular
serotypes (A, B, Ba and C) of the bacterium Chlamydia trachomatis,
and is predominantly found in the poorest countries in the world.
Active trachoma, characterised by the presence of subepithelial
follicles (trachomatous inflammation, follicular (TF)) and/or
inflammation (trachomatous inflammation, intense (TI)), is usually
found in children. After years of repeated re-infection scarring
may occur, which can lead to distortion of the eyelid, causing the
eyelashes to turn inwards (trichiasis (TT)) and scratch the cornea,
resulting in corneal opacity and blindness.[2]
The World Health Organization (WHO) strategy for Global
Elimination of Blinding Trachoma by the year 2020 (GET2020) is
through employment of the SAFE strategy (Surgery for trichiasis,
Antibiotics for active trachoma, Facial cleanliness, and Environ-
mental improvement).[3] The Gambian National Eye Care
Programme (NECP), established in 1986, expanded its national
intervention programme to cover the whole country by 1996.
NECP activities include the training of health workers in primary
eye care, surgery for trichiasis cases, recognition and treatment of
conjunctivitis, school screening, and face-washing promotion.[4]
The NECP also has a network of nyateros (Friends of the Eye) who
are non-health professionals identified by their own communities,
and have been trained to promote good eye health practices in the
community. The programme policy is to treat active trachoma
cases and household contacts with tetracycline eye ointment. At
the time the survey presented here was conducted (January to
March 2006) The Gambia was yet to receive a donation of the
antibiotic azithromycin from the International Trachoma Initia-
tive (ITI) for mass treatment.
Evidence from two national surveys carried out in 1986 and 1996
suggested that the prevalence of trachoma fell in The Gambia, with
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opacities falling from 0.10% to 0.02%. In the same time span, the
prevalence of active trachoma in 0–14 year-olds fell from 10.4% to
4.9%.[5] Disease prevalence data collected in surveys is of
importance to any national control programmes seeking to eliminate
blinding trachoma in accordance with the WHO definitions
(prevalence of TT less than 1 case per 1000 total population, and
prevalence of TF in 1–9 year-old children less than 5%).[3] Data
collected in surveys also allow control efforts to be directed to
trachoma endemic areas. However, many studies have demonstrated
that the prevalence of detected ocular C. trachomatis infection is lower
than the prevalence of active trachoma, especiallyin mass treated and
low prevalence settings.[6,7,8,9] The Gambia has not collected
infection data in its national surveys but these data may lead to a
better understanding of the disease’s epidemiology with potential
implications for the introduction of trachoma control interventions.
Mass antibiotic treatment for trachoma is likely to be effective in
treating communities with C. trachomatis infection, but of questionable
value where no infection can be demonstrated. [10,11]
We aimed to estimate the prevalence of active trachoma and
ocular C. trachomatis infection in children aged less than 10 years, a
decade after the last national survey, in Lower River Region
(LRR) and North Bank Region (NBR). These two regions had the
highest prevalence of active trachoma in children aged 0–9 years
in 1996 (11.5% and 7.7%, respectively).[5] This study reports the
results of this cluster-randomised cross-sectional survey in The
Gambia, conducted in 2006.
Methods
Ethics statement
Research was done in accordance with the declaration of
Helsinki. Ethical approval was obtained from the London School
of Hygiene and Tropical Medicine (LSHTM), UK, Ethics
Committee and The Gambia government/Medical Research
Council (MRC) Joint Ethics Committee, The Gambia. Written
(thumbprint or signature) informed consent was obtained from the
guardians of all children.
Study design
The estimated populations of NBR and LRR in 2003 were
172,835 and 72,167, respectively.[12] The sample size was
constructed for 80% power, with 95% confidence, to detect a
region prevalence of TF in 0–9 year olds above 10% if the true
prevalence was 12%, or below 10% if the true prevalence was 8%,
allowing for the geographical clustering of TF cases by assuming a
design effect of 4. The design effect shows the effect of the study
design on the estimate’s variance, and increases with cluster
sample size and within-cluster homogeneity. Since the distribution
of trachoma is clustered, and a cluster sampling strategy was
employed, a design effect of 4 adjusts the sample size to obtain the
same estimate precision as if the disease were homogenously
distributed and a simple random sample had been taken.[13,14]
The survey methods have been described in detail elsewhere.[15]
Briefly, a two-stage cluster random sampling strategy with
probability of selection proportional to size was employed. Sixty-
one enumeration areas (EAs), geographical units of approximately
the same population size, were chosen at random from the two
regions (42 in NBR and 19 in LRR). EAs are classified in The
Gambia’s census as rural or urban.[12] A household head list was
made for each selected EA and a random selection of households
was made by dividing random numbers generated in Excel (MS
Excel v2000) with the reciprocal of the number of households in the
EA. Households were selected sequentially from the top of this list,
duplicates excluded, until 50 children aged under 10 years were
included, based on the assumption that the average household size
was 7.5 people, of whom about half would be aged 0–9 years.
Reserve households were included in case 50 children could not be
obtained with the first set number of selected households.
Field methods
The day before examination, an enumeration team censused
the de facto population (those who had slept in the household the
night before) of the selected households, recording name, alias
names, age and sex. The enumeration team identified the children
aged under 10 years and informed the households that the
examination team would be coming the following day. The
examination team examined the children for clinical signs of
trachoma in the same order as they had been selected until a total
of 50 children per EA was obtained. Two experienced trachoma
clinical graders were used, who had successfully achieved a chance
corrected agreement (Cohen’s kappa statistic [16]) with the
standard over the scoring of each sign (TF, TI, TS, TT) of 0.8
or greater in validation exercises with an experienced observer
(RLB). These exercises were conducted both in the field and using
the WHO trachoma grading slides, and were further supplement-
ed using an in-house slide and photograph collection. Both eyes
were graded using a 2.56 magnifying loupe and torchlight.
Grading was according to the WHO simplified grading system and
the results of the worst eye were reported.[17] In LRR only, ocular
Dacron swabs (Hardwood Products Company, Gilford, ME, USA)
were taken from the everted tarsal conjunctiva of the child’s right
eye, using a highly standardised technique.[11] All individuals
diagnosed with trichiasis were referred to the nearest health centre
for surgery provided free of charge. Individuals with TF or TI
were offered treatment with tetracycline eye ointment. Other
ocular morbidities were managed according to NECP guidelines.
Laboratory methods
The swabs were kept cool in the field, frozen within 10 hours,
and processed by Amplicor Polymerase Chain Reaction (PCR)
assay (Roche Molecular Systems, Branchburg, NJ, USA) at MRC
Laboratories, The Gambia. A panel of samples was successfully
Author Summary
Trachoma is the leading infectious cause of blindness
worldwide, and is mainly found in tropical and poor
countries. It is caused by infection of the eyes with the
bacterium Chlamydia trachomatis. However, sometimes
the clinical signs of disease can be present without
infection being detected. Control efforts involve surgery,
antibiotic treatment, face washing, and environmental
improvement for better hygiene. Surveys of trachoma help
countries to know whether and where they should
implement control interventions. The Gambia is found in
West Africa and has suffered from trachoma for decades.
We conducted a survey of two Gambian regions to look at
how much trachoma disease and C. trachomatis infection
there is in the eyes. We found that although there was
enough disease ($10%) to warrant antibiotic treatment for
everyone in the regions, there was nearly no infection
(0.3%). This means that using clinical signs alone to make
treatment decisions in low prevalence settings like The
Gambia can lead to the waste of scarce resources. Our
results also suggest that since less than 1% of children are
infected with C. trachomatis, The Gambia is on course to
achieve the World Health Organization’s aim of eliminating
blinding trachoma by the year 2020.
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the sample results.
In order to demonstrate that adequate ocular specimens were
taken in the field, all samples were also tested for the presence of
human-specific hypervariable 1 (HV1) D-loop region mitochon-
drial DNA (mtDNA), using D-loop HV1 upper primer L15997,
59-CAC CAT TAG CAC CCA AAG CT-39 and D-loop HV1
lower primer H16236, 59-CTT TGG AGT TGC AGT TGA TG-
39 (Sigma-Genosys, Gillingham, UK).[18] The reaction mixture
contained 2 mL of Amplicor extract, 1X Quantitect SYBR Green
PCR mastermix (Qiagen, Crawley, UK), each primer at 0.3 mM,
and was made up to 10 mL with DEPC-treated sterile water. After
denaturation at 95uC for 15 minutes, samples were subjected to 45
cycles of thermal cycling (15 seconds at 95uC, 30 seconds at 60uC
and 90 seconds at 72uC) on a Rotor-Gene RG3000 (Qiagen,
Crawley, UK). The samples were analysed by melt analysis (72–
95uC), which consisted of a single hold/acquisition for 45 seconds
at 72uC and then 46 hold/acquisitions at increments of +0.5uC.
The HV1 D-loop region amplicon melted at a mean temperature
of 81.2uC (range 80.78–81.37, mean standard deviation 0.41).
During optimisation, we used gel electrophoresis to confirm the
presence of a discrete 278 bp amplicon.
Statistical analysis
Results were double-entered by different entry clerks and
verified in Microsoft Access (MS Access v2000/2003XP). Data
cleaning and analyses were performed in Stata (v9.2, STATA
Corp., College Station, TX, USA). Any discrepancies after
verification and cleaning were checked against the original paper
forms. The unadjusted prevalence of TF in 1–9 year-olds is
presented as a percentage, as standard practice for a trachoma
control programme, at EA, district, and regional levels. At regional
level, the design effect and adjusted estimates of prevalence and
corresponding 95% confidence bounds were obtained, accounting
for the two-stage sampling framework and population size. At EA
and district levels, exact binomial confidence intervals were
computed around the prevalence, as the study was designed to
have an accurate estimate of TF prevalence only at the region
level. Associations between the prevalence of TF and districts were
tested using the chi-squared (x
2) statistic. The spatial distribution
of TF prevalence by district and EA was presented graphically
using ArcView 3.3 software (Environmental Systems Research
Institute, Inc. Redlands, CA, USA).
Results
Of the 61 randomly selected EAs, 60 consented to participate. A
total of 2990 children aged 0–9 years (950 from LRR and 2040
from NBR) were examined from an estimated population of
75,000. Five children from three EAs were excluded from analyses
because they were aged over 9 years, and in five EAs only 49
children were screened.
A total of 338 children were enumerated but not examined
(Table 1). The age distribution in those examined was significantly
different from those not examined (p,0.001), with a higher
proportion examined aged 1–5 years and a lower proportion aged
6–9. The sex distribution was similar (p=0.954). The examined
population also differed from the underlying populations of LRR
and NBR established in the 2003 census,[12] but in the opposite
direction, with a lower proportion examined aged 3–6 and a
higher proportion aged 7–9 years. Adjusting for age against the
populations established by census led to a TF prevalence in
children aged 1–9 years of 13.2% in LRR and 11.3% in NBR,
versus 12.3% and 10.0% when unadjusted, respectively. This
reflects the peak TF prevalence in children aged 1–5 years.[2]
However, since trachoma control programmes usually do not
calculate adjusted prevalence rates before making treatment
decisions, we have presented unadjusted prevalences.
Prevalence of clinical signs
Overall, TF was found in 310 (10.4%) children aged 0–9 years
(Table 1). Children aged 3–5 years had the highest prevalence of
TF (17.0%), followed by those aged 1–2 years (13.1%). Children
under one year old and those aged 6–9 years had TF prevalences
of 5.6% and 6.3%, respectively. Only three (0.1%) children had TI
(two in NBR and 1 in LRR), and two of these also had TF. The
left and right eye were concordant for TF (both clinically normal
or both with TF) in 2933 (98.1%) children.
Considering the 1–9 year age group, the overall TF prevalence
(the WHO indicator) was 10.7% (95% CI 8.7–13.1). The
prevalence of TF in LRR and NBR, respectively, was 12.3%
and 10.0% (Table 2). The design effect for heterogeneity among
EAs was 3.474 overall; 3.322 for LRR and 3.561 for NBR. The
district prevalence varied significantly in LRR (p=0.006) from
5.7% to 18.2%, and in NBR (p=0.001) from 5.6% to 15.1%.
There was a trend towards higher rates in the eastern districts
compared to those in the west in LRR (x
2 test for trend p,0.001)
but not in NBR (p=0.287) (Figure 1). Prevalence also appeared to
Table 1. Age distribution of children enumerated and children examined, and prevalence of TF, TI and TS in those examined.
Age
group
(years)
Number of
children
enumerated
Number of
children
examined TF
a TI
a TS
a
Number of
cases
% of children
examined (95%
CI
b)
Number of
cases
% of children
examined (95%
CI
b)
Number of
cases
% of children
examined (95%
CI
b)
,1 263 213 12 5.6 (2.9–9.6) 0 0 (0–1.7
c) 0 0 (0–1.7
c)
1–2 579 542 71 13.1 (10.4–16.2) 2 0.4 (0.04–1.3) 3 0.6 (0.1–1.6)
3–5 851 798 136 17.0 (14,5–19.8) 0 0 (0–0.5
c) 4 0.5 (0.1–1.3)
6–9 1635 1437 91 6.3 (5.1–7.7) 1 0.1 (0.002–0.4) 17 1.2 (0.7–1.9)
Total 3328 2990 310 10.4 (9.3–11.5) 3 0.1 (0.02–0.3) 24 0.8 (0.5–1.1)
aTF=trachomatous inflammation, follicular; TI=trachomatous inflammation, intense; TS=trachomatous conjunctival scarring.
bConfidence interval.
cOne-sided, 97.5% confidence interval.
doi:10.1371/journal.pntd.0000573.t001
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in Jarra West in LRR, prevalence ranged from 0% to 36.7%, and
in Central Baddibu in NBR, prevalence ranged from 6.3% to
34.0%. Comparing the results with those from 1996 indicates little
change overall: LRR increased slightly from 11.5% to 11.9%, and
NBR increased from 7.7% to 9.7%. [5].
There were three urban EAs in LRR and nine in NBR. Overall,
53 of 552 (9.6%, 95% CI 7.3–12.4) urban children aged 1–9 years
had TF, compared with 245 of 2225 rural children (11.0%, 95%
CI 9.7–12.4). There was no evidence of variation in TF prevalence
between urban and rural EAs in either LRR (p=0.395) or NBR
(p=0.854).
Prevalence of ocular Chlamydia trachomatis infection
Only 3 of the 950 samples collected in LRR tested positive for
ocular C. trachomatis by Amplicor. Sample was available for the
testing of human-specific hypervariable D-loop region mtDNA in
942 of the 947 Amplicor-negative samples, of which 937 (99.5%)
tested positive. Thus, the prevalence of ocular C. trachomatis
infection in samples positive for human mtDNA was 0.3% (3/
940). Three field air controls (swabs waved in the air during
fieldwork to control for any field contamination) were also tested
for both ocular C. trachomatis infection and human mtDNA, giving
negative results. The three children who tested positive for ocular
C. trachomatis infection by Amplicor were aged 9, 8 and 5 years old.
One of these was in Jarra West, in an EA with a TF prevalence of
8.0% in 0–9 year-olds, and two were from Kiang East, in an EA
with a TF prevalence of 16.0% in 0–9 year-olds. Two Amplicor
positive children were clinically normal according to the WHO
simplified grading system definition, and the other had bilateral
TF. All three Amplicor positives were confirmed positive by a real-
time PCR targeting the ompA gene.[15]
Discussion
The results of this survey, covering two regions of The Gambia
with a population of approximately 245,000 people, suggest that
the overall prevalence of active trachoma in children aged 0–9
years has not noticeably changed since the 1996 national survey.
There is some evidence of a secular trend in trachoma prevalence
in The Gambia prior to 1996: in one rural village active disease
prevalence reduced from the 65.7% documented in 1959 to 2.4%
in 1996 in the absence of direct control interventions [19].
However there is no evidence that such a trend continued in LRR
and NBR between 1996 and 2006 despite trachoma control efforts
being in place in these areas. In contrast to TF, the prevalence of
C. trachomatis infection was extremely low in this survey, with only 3
of the 940 samples from LRR that were positive for human
mtDNA also testing positive for C. trachomatis. No infection data
were collected in the previous Gambian national surveys so no
trends over time can be estimated. In addition, other countries
have not collected data on ocular C. trachomatis infection when
conducting population-based surveys of active trachoma, so
between-country comparisons cannot be made. However, our
results show a lower prevalence of infection compared with
research studies conducted in The Gambia over the last two
decades.[10,20,21,22] In 1991, the prevalence of infection among
all inhabitants in two Gambian villages was 17.2%.[20] In 1999,
the overall prevalence in eight Gambian villages was 35.9%.[21]
Burton et al. reported an overall prevalence of 7.2% in 14
Gambian villages in 2003,[10] and 19.8% in two villages in
2006.[22] It is important to note that these projects were focused
on villages with notable trachoma public health problems usually
identified by finding a high prevalence of active trachoma on prior
screening, with later laboratory demonstration of high rates of
ocular C. trachomatis infection. In these villages, therefore, higher
Table 2. Prevalence of trachomatous inflammation, follicular (TF) in 1–9 year-olds by region, district, and enumeration area (EA).
Region Examined TF (%) (95% CId,e) District Examined TF (%, 95% CId,f)
No. of EAs
per district No. of EAs at prevalence (%)
0
0.1–
9.9
10–
19.9
20–
29.9
30–
39.9
LRR
a, c 876 108 Kiang West 140 8 (5.7, 2.5–10.9) 3 0 3 0 0 0
(12.3) Kiang Central 95 6 (6.3, 2.4–13.2) 2 0 2 0 0 0
(8.8–17.0) Kiang East 94 13 (13.8, 7.6–22.5) 2 0 0 2 0 0
Jarra West 319 47 (14.7, 11.0–19.1) 7 1 2 3 0 1
Jarra Central 91 9 (9.9, 4.6–17.9) 2 0 1 1 0 0
Jarra East 137 25 (18.2, 12.2–25.7) 3 0 0 2 1 0
NBR
b 1901 190 Lower Niumi 457 39 (8.5, 6.1–11.5) 10 0 7 2 1 0
(10.0) Upper Niumi 330 19 (5.6, 3.5–8.8) 7 2 4 0 1 0
(7.7–12.9) Jokadu 187 13 (7.0, 3.8–11.6) 4 1 2 0 1 0
Lower Baddibu 186 27 (14.5, 9.8–20.4) 4 1 0 2 1 0
Central Baddibu 186 28 (15.1, 10.2–21.0) 4 0 2 1 0 1
Upper Baddibu 555 64 (11.5, 9.0–14.5) 12 0 5 6 1 0
Total 2777 298 (10.7), (8.7–13.1) 2777 298 60 5 28 19 6 2
aLower River Region.
bNorth Bank Region.
cThe prevalence of ocular Chlamydia trachomatis infection in LRR in children aged 1–9 years and whose ocular swabs tested positive for human mtDNA was 0.3%
(3/866); one in Jarra West and two in Kiang East.
dConfidence interval.
e95% confidence intervals accounting for design effect.
fBinomial exact 95% confidence intervals.
doi:10.1371/journal.pntd.0000573.t002
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in the national Gambian population.
A disparity between the prevalence of active trachoma and of
ocular C. trachomatis infection has been reported by others,
especially in communities where the prevalence of disease is
declining, or in communities that have received mass treatment
with antibiotics.[6,9,10,20,23,24,25,26,27,28] Solomon et al.
observed a lag time of several years between infection elimination
and the prevalence of TF falling below 5% in a mass-treated
Tanzanian community.[7,26] In a low prevalence region of Nepal,
6.3% of children aged 1–10 years had clinical signs but no C.
trachomatis was detected.[6] Our results suggest that trachoma may
be in decline in The Gambia, with the clearance of clinical signs
lagging behind that of infection. That TF cases remain clustered
by EA with a design effect of 3.474 may suggest that previous
transmission is being captured, or that undetected infections may
have existed in close contacts. Despite diagnostic assays within the
last decade becoming increasingly more sensitive, the prevalence
of detectable C. trachomatis infection is now very low. Our
observation that the vast majority of cases were TF, with only
three cases of TI, supports this hypothesis, as TI cases are more
likely to have detectable C. trachomatis infection and with a higher
organism load.[11,21,29,30] In the one TI case tested here, C.
trachomatis infection was not detected. Clinically, our impression
was that many of the TF cases were rather mild, in the senses that
cases with very large numbers of follicles were rarely present, and
also that ‘minor signs’ of trachoma such as active pannus and
limbal follicles[31], were rare. Possibly therefore increasing the
10% TF threshold for intervention, increasing the number of
central zone follicles required to diagnose TF, and including minor
signs of trachoma in the assessment, might all improve the ability
of clinical signs to predict communities or districts with significant
ocular C. trachomatis infection. Much more data would however be
needed to justify any such departure from the current simplified
survey methods.
This association between prevalence of disease, severity of
disease, and load of C. trachomatis infection could provide another
explanation for the observed disparity between prevalence of
clinical signs and detected ocular C. trachomatis infection. The
bacterial load may have been too low for detection by Amplicor
PCR. However, the detection limit of Amplicor PCR has been
placed at about 2–4 elementary bodies (or 20–40 plasmid copies)
per 100 ml,[32] and thus even a few bacteria collected on the swab
should have yielded a positive result. The use of a Dacron
polyester-tipped swab may have lowered the PCR detection level
as it absorbs approximately 200 ml of Amplicor lysis buffer and
therefore a higher volume is required to elute the sample. The use
of a flocked swab could help overcome this.[33]
In terms of clinical grading, the two examiners were
experienced and had fulfilled the criteria of the validation sessions.
Swabs were taken according to a standardised protocol [11] by
experienced ophthalmic nurses, and 99.5% (937/942) of the
samples tested positive for human-specific mtDNA. Thus, we
believe that the observed prevalence of active trachoma, as well as
the low prevalence of ocular C. trachomatis infection, is genuine.
The follicular conjunctivitis (TF) observed in this study could
alternatively be due to organisms other than C. trachomatis. Potential
causes include adenovirus, Herpes simplex virus, Epstein Barr virus,
Molluscum contagiosum, Moraxella spp. and other species of Chlamydia,
such as C. pneumoniae, which was first isolated from the eyes of
children with trachoma.[6,34,35,36,37,38] Further laboratory
investigations to test the C. trachomatis negative swabs from clinically
active children for these other organisms may be warranted.
Our results have two important implications. The first relates to
policy decisions regarding control efforts, particularly now that
The Gambia has for the first time received a donation of
azithromycin for trachoma control. Currently, according to WHO
criteria, districts and communities with a TF prevalence greater
than or equal to 10% in children aged 1–9 years should receive
mass treatment annually, in addition to the ‘F’ and ‘E’ components
of the SAFE strategy, for at least three years, until the prevalence
of TF falls below 10%.[39] According to these criteria, 3 districts
and 10 EAs in LRR, and 3 districts and 17 EAs in NBR, should be
treated. However, our sampling strategy was designed to have an
Figure 1. Spatial distribution of TF prevalence in 1–9 year-olds in districts and sampled villages in North Bank and Lower River
Regions.
doi:10.1371/journal.pntd.0000573.g001
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the community or district level. The size of Gambian regions is
similar to the average size of a district in many countries (100,000
to 150,000 people). On this basis, our results suggest that the whole
of LRR and NBR should undergo mass treatment according to
WHO criteria, as their respective TF prevalence in 1–9 year-olds
is 12.3% and 10.0%.
Conversely, the very low prevalence of C. trachomatis infection
indicates that treatment with antibiotics is almost certainly not
necessary in many of these communities, since transmission of C.
trachomatis is now presumed to be rare. Treatment decisions based
on clinical signs of trachoma may lead to unnecessary mass
treatment of whole regions or districts, wasting the scarce resources
available, although there may be benefits beyond trachoma control
to the mass distributionof azithromycin, such as a decline on overall
mortality as shown in Ethiopia.[40] A cheap, rapid, point-of-care
test that can detect ocular C. trachomatis infection could allow policy
makers to devise treatment strategies based on the prevalence of
infection. At present, no such test is available despite previous
encouraging results [41]. Alternatively, the use of laboratory tests,
such as PCR, has been suggested as a means of detecting ocular C.
trachomatis infection. Despite reduced costs through specimen
pooling[42], national programmes are unlikely to adopt these
assays as they require expensive reagents, electricity-dependent
equipment, and highly trained technicians.[43] In the absence of a
test for infection for use by national programmes, our observation
that TF clustered by EA supports the strategy of treating households
containing someone with active trachoma in order to reach infected
but clinically normal individuals.[10]
The second implication concerns itself with the question of
whether children with clinical signs of trachoma in the absence of
C. trachomatis infection will develop blinding sequelae. The
epidemiology of trachoma is not sufficiently understood to enable
this question to be answered for certain, although the evidence
that repeated infection is required for disease progression suggests
that it is unlikely.[44,45]
This study shows a large discrepancy between the prevalence of
clinical signs and of C. trachomatis infection in two Gambian regions
in the absence of a national mass treatment programme. The
prevalence of TF in children aged less than 10 years in the two
Gambian regions that were sampled remains largely unchanged
from the prevalence 10 years ago, at around 10%. In contrast, the
prevalence of C. trachomatis infection is low (0.3%). Our results
indicate that The Gambia may not only be on course for
certification of blinding trachoma elimination according to the
WHO definition (prevalence of TT less than 1 case per 1000 total
population, and prevalence of TF in 1–9 year-old children less
than 5%)[3], but also on course to eliminate the ocular strains of C.
trachomatis prior to any mass azithromycin distribution.
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